

# ALERTA BIBLIOGRÁFICA y NOTICIAS

Respuesta rápida para casos de  
epidemias/pandemias/desastres  
naturales

Servicio Especial de la  
Biblioteca Médica Nacional

No.32 / 13 mayo 2020



## Vacunas y fármacos contra la COVID-19. Proyectos

### Descriptores DeCS

Vacunas  
Preparaciones Farmacéuticas  
Infecciones por Coronavirus  
Proyectos

### MeSH

Vaccines  
Pharmaceutical Preparations  
Coronavirus Infections  
Projects

# Bibliografía

1. **Adapt VAC. Adaptvac's ground-breaking technology central to new €2.7m EU grant funded COVID-19 vaccine effort.** [Internet]. 2020 [citado 12 May 2020]:[aprox. 9 p.]. Disponible en: <https://www.adaptvac.com/news>
2. **Apeiron Biologics. APN01.** [Internet]. 2020 [citado 12 May 2020]:[aprox. 10 p.]. Disponible en: <https://www.apeironbiologics.com/project-overview/#APN01>  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4774534/>
3. **BioNTech. BioNTech reports rapid progress on COVID-19 vaccine program to address global public health threat.** [Internet]. 2020 [citado 12 May 2020]:[aprox. 11 p.]. Disponible en: <https://investors.biontech.de/news-releases/news-releasedetails/biontech-reports-rapid-progress-COVID-19-vaccine-program-address>
4. **BioWorld. China approves first homegrown COVID-19 vaccine to enter clinical trials.** [Internet]. 2020 [citado 12 May 2020]:[aprox. 10 p.]. Disponible en: <https://www.bioworld.com/articles/433791-china-approves-first-homegrownCOVID-19-vaccine-to-enter-clinical-trials>
5. **Bundesministerium für Bildung und Forschung (BMBF). CureVac und CEPI bauen Kooperation zur Entwicklung eines Impfstoffs gegen das Coronavirus nCoV-2019 aus.** [Internet]. 2020 [citado 12 May 2020]:[aprox. 9 p.]. Disponible en: <https://www.bmbf.de/de/curevac-und-cepi-bauen-kooperation-zur-entwicklung-einesimpfstoffs-gegen-das-coronavirus-10797.html>
6. **CanSino Biologics Inc. CanSinoBIO's Investigational Vaccine Against COVID-19 Approved for Phase 1 Clinical Trial in China.** [Internet]. 2020 [citado 12 May 2020]:[aprox. 10 p.]. Disponible en: <http://www.cansinotech.com/homes/article/show/56/153.html>
7. **Canadian Pharmacists Association. Treatment of COVID-19 with chloroquine or hydroxychloroquine. Ottawa: CPhA** [Internet]. 2020 [citado 12 May 2020]:[aprox. 6 p.]. Disponible en: <https://www.pharmacists.ca/cphaca/assets/File/cpha-on-the-issues/CQ-HCQ-COVID-FINAL-EN.pdf>
8. **Cao B, Wang Y, Wen D, Liu D, Wang J, Fan G, et al. A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe COVID-19.** NEJM. [Internet]. 2020 [citado 12 May 2020]:[aprox. 8 p.]. Disponible en: <https://www.nejm.org/doi/full/10.1056/NEJMoa2001282>
9. **Centre for Evidence-Based Medicine (CEBM). Chloroquine and hydroxychloroquine: Current evidence for their effectiveness in treating COVID-19.** [Internet]. 2020 [citado 12 May 2020]:[aprox. 9 p.]. Disponible en: <https://www.cebm.net/COVID-19/chloroquine-and-hydroxychloroquine-current-evidence-for-their-effectiveness-in-treatingCOVID-19/>

10. Chen J, Liu D, Liu L, Liu P, Xu Q, Xia L, et al. **A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19).** J Zhejiang Univ (Med Sci). [Internet]. 2020 [citado 12 May 2020]:[aprox. 10 p.]. Disponible en: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7102549/>
11. Chen Z, Hu J, Zhang Z, Jiang S, Han S, Yan D, et al. **Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial.** MedRxiv. [Internet]. 2020 [citado 12 May 2020]:[aprox. 5 p.]. Disponible en: <https://www.medrxiv.org/content/medrxiv/early/2020/04/10/2020.03.22.20040758.full.pdf>
12. Chen C, Huang J, Cheng Z, Wu J, Chen S, Zhang Y, et al. **Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial.** [Internet]. 2020 [citado 12 May 2020]:[aprox. 10 p.]. Disponible en: <https://www.medrxiv.org/content/medrxiv/early/2020/04/15/2020.03.17.20037432.full.pdf>
13. Clinical Trials Arena. **First US clinical trial of COVID-19 vaccine candidate begins.** [Internet]. 2020 [citado 12 May 2020]:[aprox. 8 p.]. Disponible en: <https://www.clinicaltrialsarena.com/news/first-us-COVID-19-vaccine-trial-moderna/>
14. Coalition for Epidemic Preparedness Innovations (CEPI). **New vaccines for a safer world. Learn more about COVID-19.** [Internet]. 2020 [citado 12 May 2020]:[aprox. 10 p.]. Disponible en: <https://cepi.net/>
15. Coalition for Epidemic Preparedness Innovations (CEPI). **CEPI partners with University of Queensland to create rapid-response vaccines.** [Internet]. 2020 [citado 12 May 2020]:[aprox. 10 p.]. Disponible en: [https://cepi.net/news\\_cepi/cepipartners-with-university-of-queensland-to-create-rapid-response-vaccines/](https://cepi.net/news_cepi/cepipartners-with-university-of-queensland-to-create-rapid-response-vaccines/)
16. CureVac AG. **What We Do - The Unlimited Possibilities of mRNA. Tubingen, Germany: CureVac AG.** [Internet]. 2020 [citado 12 May 2020]:[aprox. 6 p.]. Disponible en: <https://www.curevac.com/mrna-platform>.
17. CureVac AG. **CureVac and CEPI extend their Cooperation to Develop a Vaccine against Coronavirus nCoV-2019 Tubingen, Germany: CureVac AG.** [Internet]. 2020 [citado 12 May 2020]:[aprox. 9 p.]. Disponible en: <https://www.curevac.com/news/curevac-and-cepi-extend-their-cooperation-to-develop-a-vaccine-against-coronavirus-ncov-2019>
18. CureVac AG. **CureVac Announces Positive Results in Low Dose – 1 µg – Rabies Vaccine Clinical Phase 1 Study Tubingen, Germany: CureVac AG.** [Internet]. 2020 [citado 12 May 2020]:[aprox. 7 p.]. Disponible en: <https://www.curevac.com/news/curevac-announces-positive-results-in-low-dose-1-µg-rabiesvaccine-clinical-phase-1-study>

19. CureVac AG. **COVID-19: Conference Call on Current Developments. Tubingen, Germany: CureVac AG.** [Internet]. 2020 [citado 12 May 2020]:[aprox. 6 p.]. Disponible en: <https://www.curevac.com/news/conference-call-on-current-developments>
20. CureVac AG. **CureVac CEO Daniel Menichella Discusses Coronavirus Vaccine Development with U.S. President Donald Trump and Members of Coronavirus Task Force Tubingen, Germany: CureVac AG.** [Internet]. 2020 [citado 12 May 2020]:[aprox. 10 p.]. Disponible en: <https://www.curevac.com/news/curevac-ceo-danielmenichella-berat-mit-us-prasident-donald-trump-und-mitgliedern-der-corona-task-orceentwicklungsmoglichkeiten-eines-coronavirus-impfstoffes>
21. CureVac AG. **Our pipeline: mRNA-based Prophylactic Vaccines. Tubingen, Germany: CureVac AG.** [Internet]. 2020 [citado 12 May 2020]:[aprox. 10 p.]. Disponible en: <https://www.curevac.com/our-pipeline>
22. Denis M, Vanderweerd V, Verbeke R, Van der Vliet D. **Overview of information available to support the development of medical countermeasures and interventions against COVID-19. Living document.** [Internet]. 2020 [citado 12 May 2020]:[aprox. 7 p.]. Disponible en: [https://rega.kuleuven.be/if/pdf\\_corona](https://rega.kuleuven.be/if/pdf_corona)
23. Dong L, Hu S, Gao J. **Discovering drugs to treat coronavirus disease 2019 (COVID-19).** Drug Discoveries & Therapeutics. [Internet]. 2020 [citado 12 May 2020]:[aprox. 8 p.]. Disponible en: [https://www.jstage.jst.go.jp/article/ddt/14/1/14\\_2020.01012/\\_pdf](https://www.jstage.jst.go.jp/article/ddt/14/1/14_2020.01012/_pdf)
24. **Drug Development and Delivery. Novavax Advances Development of Novel COVID-19 Vaccine.** [Internet]. 2020 [citado 12 May 2020]:[aprox. 9 p.]. Disponible en: <https://drug-dev.com/novavax-advances-development-of-novelCOVID-19-vaccine/>
25. European Commission. **New research projects on Coronavirus. Outcome of emergency funding action for coronavirus SARS-CoV-2 outbreak: 17 new projects.** [Internet]. 2020 [citado 12 May 2020]:[aprox. 11 p.]. Disponible en:[https://ec.europa.eu/info/sites/info/files/research\\_and\\_innovation/research\\_by\\_area/documents/ec\\_rtd\\_cv-projects.pdf?fbclid=IwAR27kaCByfkkpaEZFHJsisUifPq3O6nT1ukFvk8knHkN6qVGuxvlu-Q0eE](https://ec.europa.eu/info/sites/info/files/research_and_innovation/research_by_area/documents/ec_rtd_cv-projects.pdf?fbclid=IwAR27kaCByfkkpaEZFHJsisUifPq3O6nT1ukFvk8knHkN6qVGuxvlu-Q0eE)
26. European Medicines Agency (EMA). **Global regulators stress need for robust evidence on COVID-19 treatments.** [Internet]. 2020 [citado 12 May 2020]:[aprox. 8 p.]. Disponible en: <https://www.ema.europa.eu/en/news/global-regulators-stressneed-robust-evidence-COVID-19-treatments>
27. European Medicines Agency (EMA). **EMA establishes task force to take quick and coordinated regulatory action related to COVID-19 medicines.** [Internet]. 2020 [citado 12 May 2020]:[aprox. 9 p.]. Disponible en:

- [https://www.ema.europa.eu/en/documents/press-release/ema-establishes-task-force-takequick-coordinated-regulatory-action-related-COVID-19-medicines\\_en.pdf](https://www.ema.europa.eu/en/documents/press-release/ema-establishes-task-force-takequick-coordinated-regulatory-action-related-COVID-19-medicines_en.pdf)
28. European Medicines Agency (EMA). **EPAR summary for the public: Kevzara (sarilumab)**. [Internet]. 2020 [citado 12 May 2020]:[aprox. 10 p.]. Disponible en: [https://scholar.google.com/scholar?output=instlink&q=info:zEvykL19pOIJ:scholar.google.com/&hl=es&as\\_sdt=0,5&scillfp=4387600827117166204&oi=lle](https://scholar.google.com/scholar?output=instlink&q=info:zEvykL19pOIJ:scholar.google.com/&hl=es&as_sdt=0,5&scillfp=4387600827117166204&oi=lle)
  29. European Medicines Agency (EMA). **EMA provides recommendations on compassionate use of remdesivir for COVID-19**. [Internet]. 2020 [citado 12 May 2020]:[aprox. 10 p.]. Disponible en: <https://www.ema.europa.eu/en/news/ema-provides-recommendations-compassionate-useremdesivir-COVID-19>
  30. European Medicines Agency. **RoActemra (tocilizumab)**. Amsterdam: EMA. [Internet]. 2020 [citado 12 May 2020]:[aprox. 6 p.]. Disponible en:<https://www.ema.europa.eu/en/medicines/human/EPAR/roactemra>
  31. European Commission. Coronavirus: **Commission offers financing to innovative vaccines Company CureVac**. [Internet]. 2020 [citado 12 May 2020]:[aprox. 9 p.]. Disponible en: [https://ec.europa.eu/commission/presscorner/detail/en/IP\\_20\\_474](https://ec.europa.eu/commission/presscorner/detail/en/IP_20_474)
  32. FierceBiotech. **Pfizer, BioNTech strike COVID-19 deal, commit multiple R&D sites to vaccine development**. [Internet]. 2020 [citado 12 May 2020]:[aprox. 7 p.]. Disponible en: <https://www.fiercebiotech.com/biotech/pfizer-biontech-strike-COVID-19-deal-commit-multiple-rd-sites-to-vaccine-development>
  33. Food and Drug Administration (FDA). **Coronavirus (COVID-19) Update: FDA Continues to Facilitate Development of Treatments**. [Internet]. 2020 [citado 12 May 2020]:[aprox. 10 p.]. Disponible en: <https://www.fda.gov/news-events/press-announcements/coronavirus-COVID-19-update-fdacontinues-facilitate-development-treatments>
  34. Fundacion Epistemonikos. **Systematic review - preliminary report Lopinavir/ritonavir for the treatment of COVID-19**. [Internet]. 2020 [citado 12 May 2020]:[aprox. 9 p.]. Disponible en: <https://www.epistemonikos.cl/2020/03/20/systematic-review-preliminary-report-opinavirritonavir-for-the-treatment-of-COVID-19/>
  35. Fujii S, Hitomi Y. **New synthetic inhibitors of C1r, C1 esterase, thrombin, plasmin, kallikrein and trypsin**. Biochim Biophys Acta. [Internet]. 2020 [citado 12 May 2020]:[aprox. 7 p.]. Disponible en: <https://www.sciencedirect.com/science/article/pii/S0092867420302294>
  36. Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. **Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial**. Int J Antimicrob Agents. [Internet]. 2020

- [citado 12 May 2020]:[aprox. 6 p.]. Disponible en: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7102549/>
37. Hennessy J. **Australia's been asked to make a coronavirus vaccine at 'unprecedented speed' business insider.** [Internet]. 2020 [citado 12 May 2020]:[aprox. 8 p.]. Disponible en: <https://www.sciencealert.com/australian-scientists-asked-to-make-coronavirus-vaccine-at-unprecedented-speed>
  38. Hodgson J. **The pandemic pipeline.** [Internet]. 2020 [citado 12 May 2020]:[aprox. 7 p.]. Disponible en: <https://www.nature.com/articles/d41587-020-00005-z>
  39. Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, et al. **SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.** Cell. [Internet]. 2020 [citado 12 May 2020]:[aprox. 9 p.]. Disponible en: [https://doi.org/10.1016/0005-2744\(81\)90023-1](https://doi.org/10.1016/0005-2744(81)90023-1)  
<https://www.sciencedirect.com/science/article/abs/pii/S0005274481900231>
  40. Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, et al. **First Case of 2019 Novel Coronavirus in the United States.** New England Journal of Medicine. [Internet]. 2020 [citado 12 May 2020]:[aprox. 10 p.]. Disponible en: <https://www.nejm.org/doi/full/10.1056/NEJMoa2001191>
  41. HTA Austria. Austrian Institute for Health Technology Assessment GmbH Garnisongasse. **COVID-19 HSS/ Horizon Scanning. Living Document V01 Part 1.** AIHTA. [Internet]. 2020 [citado 12 May 2020]:[aprox. 10 p.]. Disponible en: [http://eprints.aihta.at/1234/1/Policy\\_Brief\\_002.pdf](http://eprints.aihta.at/1234/1/Policy_Brief_002.pdf)
  42. Huang M, Tang T, Pang P, Li M, Ma R, Lu J, et al. **Treating COVID-19 with Chloroquine.** Journal of Molecular Cell Biology. [Internet]. 2020 [citado 12 May 2020]:[aprox. 9 p.]. Disponible en: <https://doi.org/10.1093/jmcb/mjaa014>
  43. Inovio Pharmaceuticals. **Inovio Accelerates Timeline for COVID-19 DNA Vaccine INO-4800.** [Internet]. 2020 [citado 12 May 2020]:[aprox. 10 p.]. Disponible en: <http://ir.inovio.com/news-and-media/news/press-releasedetails/2020/Inovio-Accelerates-Timeline-for-COVID-19-DNA-Vaccine-INO-4800/default.aspx>
  44. Inovio Pharmaceuticals. **Inovio Collaborating With Beijing Advaccine To Advance INO-4800 Vaccine Against New Coronavirus In China.** [Internet]. 2020 [citado 12 May 2020]:[aprox. 9 p.]. Disponible en: <http://ir.inovio.com/newsand-media/news/press-release-details/2020/Inovio-Collaborating-With-Beijing-Advaccine-To-Advance-INO-4800-Vaccine-Against-New-Coronavirus-In-China/default.aspx>
  45. Institut national d'excellence en sante et en services sociaux (INESSS). **COVID-19 et interferons. Quebec, Qc: Gouvernement du Quebec.** [Internet]. 2020 [citado 12 May 2020]:[aprox. 8 p.]. Disponible en:



[https://www.inesss.qc.ca/fileadmin/doc/INESSS/COVID-19/COVID-19\\_interferons.pdf](https://www.inesss.qc.ca/fileadmin/doc/INESSS/COVID-19/COVID-19_interferons.pdf)

46. Jackson LA. **Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis SARS CoV-2 Infection.** [Internet]. 2020 [citado 12 May 2020]:[aprox. 5 p.]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT04283461.Jackson>
47. Karolinska Institutet. **Vaccine development against coronavirus enters next phase.** [Internet]. 2020 [citado 12 May 2020]:[aprox. 9 p.]. Disponible en: <https://news.ki.se/vaccine-development-against-coronavirus-enters-next-phase>
48. Karolinska Institutet. **Three KI-led coronavirus projects selected in EU funding round.** [Internet]. 2020 [citado 12 May 2020]:[aprox. 10 p.]. Disponible en: <https://news.ki.se/three-ki-led-coronavirus-projects-selected-in-eu-funding-round>
49. Kawase M, Shirato K, van der Hoek L, Taguchi F, Matsuyama S. **Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors** [Internet]. 2020 [citado 12 May 2020]:[aprox. 10 p.]. Disponible en: [https://scholar.google.com/scholar?output=instlink&q=info:vgWYMEj4Q9cJ:scholar.google.com/&hl=es&as\\_sdt=0,5&scillfp=6461270290173073583&oi=lle](https://scholar.google.com/scholar?output=instlink&q=info:vgWYMEj4Q9cJ:scholar.google.com/&hl=es&as_sdt=0,5&scillfp=6461270290173073583&oi=lle)  
<https://jvi.asm.org/content/jvi/86/12/6537.full.pdf>
50. Keown A. **Pfizer and BioNTech to Develop mRNA Vaccine for COVID-19.** BioSpace. [Internet]. 2020 [citado 12 May 2020]:[aprox. 11 p.]. Disponible en: <https://www.biospace.com/article/pfizer-and-biontech-to-develop-mrna-vaccine-forCOVID-19/>
51. Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, et al. **A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury.** Nature medicine. [Internet]. 2020 [citado 12 May 2020]:[aprox. 8 p.]. Disponible en: <https://www.nature.com/articles/nm1267>
52. Kupferschmidt K, Cohen J. **Race to find COVID-19 treatments accelerates.** Science. [Internet]. 2020 [citado 12 May 2020]:[aprox. 10 p.]. Disponible en: <http://www.theunreasonablemanblog.com/wp-content/uploads/2020/04/Race-to-Find-COVID-19-Treatments-Accelerates-Kupferschmidt-Cohen-Science-2020.pdf>
53. Labor Journal. **Alle gegen einen. Das Coronavirus halt Biotech-Firmen weltweit auf Trab. Die einen entwickeln Apps, die anderen Impfstoffe.** [Internet]. 2020 [citado 12 May 2020]:[aprox. 9 p.]. Disponible en: <https://www.laborjournal.de/editorials/1964.php>
54. Lu C-C, Chen M-Y, Chang Y-L. **Potential therapeutic agents against COVID-19: What we know so far.** Journal of the Chinese Medical Association. [Internet]. 2020 [citado 12 May 2020]:[aprox. 10 p.]. Disponible en: [https://idp.springer.com/authorize/casa?redirect\\_uri=https://link.springer.com/content/pdf/10.1007/s11684-020-0767-](https://idp.springer.com/authorize/casa?redirect_uri=https://link.springer.com/content/pdf/10.1007/s11684-020-0767-)

[8.pdf&casa\\_token=Agk\\_DgaAwTYAAAA:sTuHsl\\_GFyiKiDzypDW2P2Q34ZAgkGhtT7\\_UhqpbVA7uxvlhvV-43Zty7oYG4-rpFGmVZUW2eyygRFUfueE](#)

55. McKeage K, Perry CM, Keam SJ. **Darunavir: a review of its use in the management of HIV infection in adults.** Drugs. [Internet]. 2020 [citado 12 May 2020]:[aprox. 8 p.]. Disponible en: <https://doi.org/10.1007/s40265-013-0159-3>
56. Monteil V, Hyesoo Kwon, Patricia Prado, Astrid Hagelkruys, Reiner A. Wimmer, Martin Stahl, et al. **Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2.** [Internet]. 2020 [citado 12 May 2020]:[aprox. 8 p.]. Disponible en: [https://www.cell.com/pbassets/products/coronavirus/CELL\\_CELL-D-20-00739.pdf](https://www.cell.com/pbassets/products/coronavirus/CELL_CELL-D-20-00739.pdf)
57. Murdoch D, Lyseng-Williamson KA. **Spotlight on subcutaneous recombinant interferon-beta-1a (Rebif) in relapsing-remitting multiple sclerosis.** BioDrugs. [Internet]. 2020 [citado 12 May 2020]:[aprox. 10 p.]. Disponible en: <https://doi.org/10.2165/00063030-200519050-00005>
58. National Institute of Health (NIH). **NIH clinical trial of investigational vaccine for COVID-19 begins.** [Internet]. 2020 [citado 12 May 2020]:[aprox. 9 p.]. Disponible en: <https://www.nih.gov/news-events/news-releases/nihclinical-trial-investigational-vaccine-COVID-19-begins>
59. Nature biotechnology. **The pandemic pipeline.** [Internet]. 2020 [citado 12 May 2020]:[aprox. 5 p.]. Disponible en: <https://www.nature.com/articles/d41587-020-00005-z>
60. Nature. **A surprising player in the race for a SARS-CoV-2 vaccine.** [Internet]. 2020 [citado 12 May 2020]:[aprox. 10 p.]. Disponible en: <https://www.nature.com/articles/d42473-020-00032-z>
61. Novavax. **Novavax Awarded Funding from CEPI for COVID-19 Vaccine Development.** [Internet]. 2020 [citado 12 May 2020]:[aprox. 7 p.]. Disponible en: <https://ir.novavax.com/news-releases/news-release-details/novavaxawarded-funding-cepi-COVID-19-vaccine-development>
62. Novavax. **Matrix-M™ Adjuvant Technology.** [Internet]. 2020 [citado 12 May 2020]:[aprox. 9 p.]. Disponible en: <https://novavax.com/page/10/matrix-m-adjuvant-technology.html>
63. Pang J, Wang MX, Ang IYH, Tan SHX, Lewis RF, Chen JI, et al. **Potential Rapid Diagnostics, Vaccine and Therapeutics for 2019 Novel Coronavirus (2019-nCoV): A Systematic Review.** Journal of clinical medicine. [Internet]. 2020 [citado 12 May 2020]:[aprox. 10 p.]. Disponible en: <https://doi.org/10.3390/jcm9030623>  
<https://www.mdpi.com/2077-0383/9/3/623/pdf>



64. Pfizer. **Pfizer and Biontech to co-develop potential COVID-19 vaccine.** [Internet]. 2020 [citado 12 May 2020]:[aprox. 11 p.]. Disponible en: [http://pfizer.com/news/press-release/press-releasedetail/pfizer and biontech to co develop potential covid 19 vaccine](http://pfizer.com/news/press-release/press-releasedetail/pfizer-and-biontech-to-co-develop-potential-covid-19-vaccine)
65. Precision vaccination. **Ad5-nCoV COVID-19 Vaccine.** [Internet]. 2020 [citado 12 May 2020]:[aprox. 9 p.]. Disponible en: <https://www.precisionvaccinations.com/vaccines/ad5-ncov-COVID-19-vaccine>
66. Precision vaccination. **SARS-CoV-2 Vaccine Candidate Ready For Clinical Study. Inovio Pharmaceuticals INO-4800 vaccine candidate prepares for human studies.** [Internet]. 2020 [citado 12 May 2020]:[aprox. 10 p.]. Disponible en: <https://www.precisionvaccinations.com/inovio-pharmaceuticals-ino-4800-vaccine-candidateprepares-human-studies>
67. **Should favipiravir be used for COVID-19? Ministry of Health Singapore and Agency for Care Effectiveness.** [Internet]. 2020 [citado 12 May 2020]:[aprox. 7 p.]. Disponible en: [https://www.moh.gov.sg/docs/librariesprovider5/clinical-evidence-ummaries/favipiravir-forCOVID-19-\(26-march-2020\).pdf](https://www.moh.gov.sg/docs/librariesprovider5/clinical-evidence-ummaries/favipiravir-forCOVID-19-(26-march-2020).pdf)
68. Stackpool I. **Australian scientists claim they've ALREADY developed a vaccine for coronavirus - but they can't roll it out to people just yet.** [Internet]. 2020 [citado 12 May 2020]:[aprox. 8 p.]. Disponible en: <https://www.dailymail.co.uk/news/article-8110909/Australian-scientists-say-vaccine-deadlycoronavirus-roll-yet.html>
69. Themis Bioscience. **CEPI collaborates with the Institut Pasteur in a consortium to develop COVID-19 vaccine** [Internet]. 2020 [citado 12 May 2020]:[aprox. 9 p.]. Disponible en: <https://www.themisbio.com/cepi-collaborates-with-the-institutpasteur-in-a-consortium-to-develop-COVID-19-vaccine/>
70. The University of Queensland. **Race to develop coronavirus vaccine.** [Internet]. 2020 [citado 12 May 2020]:[aprox. 8 p.]. Disponible en: <https://www.uq.edu.au/news/article/2020/01/race-develop-coronavirus-vaccine>
71. University of Oxford. **Oxford team to begin novel coronavirus vaccine research.** [Internet]. 2020 [citado 12 May 2020]:[aprox. 11 p.]. Disponible en: <http://www.ox.ac.uk/news/2020-02-07-oxford-team-begin-novel-coronavirusvaccine-research>
72. U.S. National Library of Medicine. **A Phase I Clinical Trial in 18-60 Adults (APICTH).** [Internet]. 2020 [citado 12 May 2020]:[aprox. 9 p.]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT04313127>
73. U.S. National Library of Medicine. **A Study of a Candidate COVID-19 Vaccine (COV001).** [Internet]. 2020 [citado 12 May 2020]:[aprox. 10 p.]. Disponible en: <https://clinicaltrials.gov/ct2/show/NCT04324606>

74. Verband der forschenden Pharmaunternehmen (VfA). **Impfstoffe zum Schutz vor COVID-19, der neuen Coronavirus-Infektion; Therapeutische Medikamente gegen die Coronavirusinfektion COVID-19.** [Internet]. 2020 [citado 12 May 2020]:[aprox. 10 p.]. Disponible en: <https://www.vfa.de/de/arzneimittel-forschung/woran-wir-forschen/impfstoffezum-schutz-vor-coronavirus-2019-ncov>  
<https://www.vfa.de/de/arzneimittel-forschung/woranwir-forschen/therapeutische-medikamente-gegen-die-coronavirusinfektion-COVID-19>
75. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. **Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.** [Internet]. 2020 [citado 12 May 2020]:[aprox. 10 p.]. Disponible en: <https://www.nature.com/articles/s41422-020-0282-0?fbclid=IwAR3c5iy9h65X1cnkrL6i6fJcWwi0ygN1LtI67SkcgREM4DyxxAcPauRuf5w>
76. World Health Organisation (WHO). **DRAFT landscape of COVID-19 candidate vaccines.** [Internet]. 2020 [citado 12 May 2020]:[aprox. 10 p.]. Disponible en: <https://www.who.int/blueprint/priority-diseases/keyaction/novel-coronavirus-landscape-ncov-21march2020.PDF?ua=1>
77. World Health Organisation (WHO). **DRAFT landscape of COVID-19 candidate vaccines.** [Internet]. 2020 [citado 12 May 2020]:[aprox. 10 p.]. Disponible en: <https://www.who.int/blueprint/priority-diseases/keyaction/novel-coronavirus-landscape-ncov-21march2020.PDF?ua=1>
78. Xie M, Chen Q. **Insight into 2019 novel coronavirus - an updated intrim review and lessons from SARSCoV and MERS-CoV.** Int J Infect Dis. [Internet]. 2020 [citado 12 May 2020]:[aprox. 10 p.]. Disponible en: <https://doi.org/10.1016/j.ijid.2020.03.071>
79. Xu X, Han M, Li T, Sun W, Dongsheng W, Fu B, et al. **Effective Treatment of Severe COVID-19 Patients with Tocilizumab.** [Internet]. 2020 [citado 12 May 2020]:[aprox. 10 p.]. Disponible en: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7176266/>
80. Yao X, Ye F, Zhang M, Cui C, Huang B, Nu P, et al. **In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the T treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).** Clin Infect Dis. [Internet]. 2020 [citado 12 May 2020]:[aprox. 10 p.]. Disponible en: <https://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciaa237/33166252/ciaa237.pdf>
81. Zhang C, Huang S, Zheng F, Dai Y. **Controversial treatments: an updated understanding of the Coronavirus Disease 2019.** Journal of Medical Virology. [Internet]. 2020 [citado 12 May 2020]:[aprox. 10 p.]. Disponible en: <https://doi.org/10.1002/jmv.25788>
82. Zhou M, Zhang X, Qu J. **Coronavirus disease 2019 (COVID-19): a clinical update.** Frontiers of Medicine. [Internet]. 2020 [citado 12 May 2020]:[aprox. 10 p.]. Disponible en:

[https://idp.springer.com/authorize/casa?redirect\\_uri=https://link.springer.com/content/pdf/10.1007/s11684-020-0767-8.pdf&casa\\_token=Agk\\_DgaAwTYAAAA:sTuHsl\\_GFyiKiDzypDW2P2Q34ZAgkGhtT7UhqpbVA7uxvlhvV-43Zty7oYG4-rpFGmVZUW2eyygRFUfueE](https://idp.springer.com/authorize/casa?redirect_uri=https://link.springer.com/content/pdf/10.1007/s11684-020-0767-8.pdf&casa_token=Agk_DgaAwTYAAAA:sTuHsl_GFyiKiDzypDW2P2Q34ZAgkGhtT7UhqpbVA7uxvlhvV-43Zty7oYG4-rpFGmVZUW2eyygRFUfueE)

83. Zhou Y, Vedantham P, Lu K, Agudelo J, Carrion R, Jr., Nunneley JW, et al. **Protease inhibitors targeting coronavirus and filovirus entry.** Antiviral Res. [Internet]. 2020 [citado 12 May 2020]:[aprox. 10 p.]. Disponible en: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4774534/>

**BASES DE DATOS CONSULTADAS:** PUBMED/MEDLINE, SCIEDIRECT, MEDRXIV, SCHOLAR GOOGLE

**Compilación:** Dra.C. Maria del Carmen González Rivero

## Documentos relacionados

1. Biblioteca EUECR. **Brief Summary of Potential SARS-CoV-2 Prophylactic and Treatment Drugs in the Emergency Department.** [Internet]. 2020 [citado 12 May 2020]:[aprox. 8 p.]. Disponible en: [https://drive.google.com/file/d/1zNK7AJDbsfDdALxD\\_KLkw-Jx5zi7TcD5/view?usp=drive\\_web](https://drive.google.com/file/d/1zNK7AJDbsfDdALxD_KLkw-Jx5zi7TcD5/view?usp=drive_web)
2. Biblioteca EUECR. **Computers and viral diseases. Preliminary bioinformatics studies on the design of a synthetic vaccine and a preventative peptidomimetic antagonist against the SARS-CoV-2 (2019-nCoV, COVID-19).** [Internet]. 2020 [citado 12 May 2020]:[aprox. 5 p.]. Disponible en: [https://drive.google.com/file/d/1dZXsu7698XJ5QMjCBiZ9BtU-dEk5r-w2/view?usp=drive\\_web](https://drive.google.com/file/d/1dZXsu7698XJ5QMjCBiZ9BtU-dEk5r-w2/view?usp=drive_web)
3. Biblioteca EUECR. **Considering BCG vaccination to reduce the impact of COVID-19.** [Internet]. 2020 [citado 12 May 2020]:[aprox. 10 p.]. Disponible en: [https://drive.google.com/file/d/1D1N-sYZW2McG09FbtU\\_sIFLRCd6FhMdB/view?usp=drive\\_web](https://drive.google.com/file/d/1D1N-sYZW2McG09FbtU_sIFLRCd6FhMdB/view?usp=drive_web)
4. Biblioteca EUECR. **Vaccine confidence in the time of COVID-19.** [Internet]. 2020 [citado 12 May 2020]:[aprox. 4 p.]. Disponible en: [https://drive.google.com/file/d/1YhGhcypFUznHyCreTtswBCJaX66Lj6vt/view?usp=drive\\_web](https://drive.google.com/file/d/1YhGhcypFUznHyCreTtswBCJaX66Lj6vt/view?usp=drive_web)
5. Biblioteca EUECR. **What Does Plant-Based Vaccine Technology Offer to the Fight against COVID-19.** [Internet]. 2020 [citado 12 May 2020]:[aprox. 6 p.]. Disponible en: [https://drive.google.com/file/d/1hXWYh3bx-gGBCEiNGwE7bV6FG\\_is1eNz/view?usp=drive\\_web](https://drive.google.com/file/d/1hXWYh3bx-gGBCEiNGwE7bV6FG_is1eNz/view?usp=drive_web)
6. **COVID-19, an emerging coronavirus infection\_ advances and prospects in designing and developing vaccines, immunotherapeutics, and Therapeutics.** [Internet]. 2020 [citado 12 May 2020]:[aprox. 7 p.]. Disponible en:

[https://drive.google.com/file/d/1ioCiKmLO3oUUtUq38DW85UuUuH8Fd0v\\_/view?usp=drive\\_web](https://drive.google.com/file/d/1ioCiKmLO3oUUtUq38DW85UuUuH8Fd0v_/view?usp=drive_web)

7. **COVID-19: ¿What do we know so far about a vaccine?** [Internet]. 2020 [citado 12 May 2020]:[aprox. 6 p.]. Disponible en: [https://drive.google.com/file/d/1m91DoBQV3GOdzMvkupmNhA3sL8dPhbwa/view?usp=drive\\_web](https://drive.google.com/file/d/1m91DoBQV3GOdzMvkupmNhA3sL8dPhbwa/view?usp=drive_web)
8. **Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 COVID-19.** [Internet]. 2020 [citado 12 May 2020]:[aprox. 8 p.]. Disponible en: [https://drive.google.com/file/d/1wceq-R3illcTzWiOIG8KCPfLryNYQWlg/view?usp=drive\\_web](https://drive.google.com/file/d/1wceq-R3illcTzWiOIG8KCPfLryNYQWlg/view?usp=drive_web)
9. **Development of an inactivated vaccine candidate for SARS-CoV-2.** [Internet]. 2020 [citado 12 May 2020]:[aprox. 6 p.]. Disponible en: [https://drive.google.com/file/d/1g4-GeZVz3p2AZiA7oGISx01IHknw5Quc/view?usp=drive\\_web](https://drive.google.com/file/d/1g4-GeZVz3p2AZiA7oGISx01IHknw5Quc/view?usp=drive_web)
10. **Development of epitope-based peptide vaccine against novel Coronavirus 2019 (SARS-COV-2) Immunoinformatics approach.** [Internet]. 2020 [citado 12 May 2020]:[aprox. 5 p.]. Disponible en: [https://drive.google.com/file/d/1en6YHUMSiyJuU79sfszCZyh\\_9Rov3vSx/view?usp=drive\\_web](https://drive.google.com/file/d/1en6YHUMSiyJuU79sfszCZyh_9Rov3vSx/view?usp=drive_web)
11. **El programa de inmunización en el contexto de la pandemia de COVID-19 Versión 2 24 de abril 2020\_OPS.** [Internet]. 2020 [citado 12 May 2020]:[aprox. 9 p.]. Disponible en: [https://drive.google.com/file/d/1tI7uljUwU5wvfc022gCCfZqg2JLdV59L/view?usp=drive\\_web](https://drive.google.com/file/d/1tI7uljUwU5wvfc022gCCfZqg2JLdV59L/view?usp=drive_web)
12. **Human challenge studies to accelerate coronavirus vaccine licensure.** [Internet]. 2020 [citado 12 May 2020]:[aprox. 7 p.]. Disponible en: [https://drive.google.com/file/d/1Rs3RrNSQqk6GJHmULP3nlue\\_raseCyX/view?usp=drive\\_web](https://drive.google.com/file/d/1Rs3RrNSQqk6GJHmULP3nlue_raseCyX/view?usp=drive_web)
13. **Immune responses in COVID-19 and potential vaccines\_Lessons learned from SARS and MERS epidemic.** [Internet]. 2020 [citado 12 May 2020]:[aprox. 5 p.]. Disponible en: [https://drive.google.com/file/d/1ecLdp1FoJbcrBX2\\_S7zCLBlwcV-03wl8/view?usp=drive\\_web](https://drive.google.com/file/d/1ecLdp1FoJbcrBX2_S7zCLBlwcV-03wl8/view?usp=drive_web)
14. **Immunoinformatics-aided identification of T cell and B cell epitopes in the surface glycoprotein of 2019-nCoV.** [Internet]. 2020 [citado 12 May 2020]:[aprox. 7 p.]. Disponible en: [https://drive.google.com/file/d/1qy7cWHrtAwOhCHltXvseGC7U-GMagnsx/view?usp=drive\\_web](https://drive.google.com/file/d/1qy7cWHrtAwOhCHltXvseGC7U-GMagnsx/view?usp=drive_web)
15. **Microneedle array delivered recombinant coronavirus vaccines\_ Immunogenicity and rapid translational development.** [Internet]. 2020 [citado 12 May 2020]:[aprox. 4 p.]. Disponible en: [https://drive.google.com/file/d/1yRwTpw-HEV8ut69Tgw3bGa3WaiByGtI3/view?usp=drive\\_web](https://drive.google.com/file/d/1yRwTpw-HEV8ut69Tgw3bGa3WaiByGtI3/view?usp=drive_web)

16. **Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies.** [Internet]. 2020 [citado 12 May 2020]:[aprox. 7 p.]. Disponible en: [https://drive.google.com/file/d/1MfvoDPcEdc8kY3YGsPMC5ZAFqMXDyJm7/view?usp=drive\\_web](https://drive.google.com/file/d/1MfvoDPcEdc8kY3YGsPMC5ZAFqMXDyJm7/view?usp=drive_web)
17. **Progress and Prospects on Vaccine Development against SARS-CoV-2.** [Internet]. 2020 [citado 12 May 2020]:[aprox. 6 p.]. Disponible en: [https://drive.google.com/file/d/1EcgziPiOtNG9H5Z\\_3bPzxcasPtI2U\\_bF/view?usp=drive\\_web](https://drive.google.com/file/d/1EcgziPiOtNG9H5Z_3bPzxcasPtI2U_bF/view?usp=drive_web)
18. **Rapid COVID-19 vaccine development.** [Internet]. 2020 [citado 12 May 2020]:[aprox. 8 p.]. Disponible en: [https://drive.google.com/file/d/13IPeSocvl-AXikBBOvC5Osl7-dOqSjDE/view?usp=drive\\_web](https://drive.google.com/file/d/13IPeSocvl-AXikBBOvC5Osl7-dOqSjDE/view?usp=drive_web)
19. **SARS-CoV-2 Vaccines\_Status Report.** [Internet]. 2020 [citado 12 May 2020]:[aprox. 9 p.]. Disponible en: [https://drive.google.com/file/d/14qJMxShpsUJsFjLoj1ZK07ajNZNjDbcV/view?usp=drive\\_web](https://drive.google.com/file/d/14qJMxShpsUJsFjLoj1ZK07ajNZNjDbcV/view?usp=drive_web)
20. Biblioteca EUECR. **The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines.** [Internet]. 2020 [citado 12 May 2020]:[aprox. 5 p.]. Disponible en: [https://drive.google.com/file/d/1eddEgXpATjvI7JixlwwJMs3MtkKzFVdx/view?usp=drive\\_web](https://drive.google.com/file/d/1eddEgXpATjvI7JixlwwJMs3MtkKzFVdx/view?usp=drive_web)
21. **The Potential Role of Th17 Immune Responses in Coronavirus Immunopathology and Vaccine-induced Immune Enhancement.** [Internet]. 2020 [citado 12 May 2020]:[aprox. 6 p.]. Disponible en: [https://drive.google.com/file/d/1899EredFXDEq3sENU8nXiODSI1ywD9nG/view?usp=drive\\_web](https://drive.google.com/file/d/1899EredFXDEq3sENU8nXiODSI1ywD9nG/view?usp=drive_web)
22. **The SARS-CoV-2 Vaccine Pipeline\_an Overview.** [Internet]. 2020 [citado 12 May 2020]:[aprox. 9 p.]. Disponible en: [https://drive.google.com/file/d/1IG4yuBCBO2GrikE2WBZx9kGfkzYkToSr/view?usp=drive\\_web](https://drive.google.com/file/d/1IG4yuBCBO2GrikE2WBZx9kGfkzYkToSr/view?usp=drive_web)
23. **Tuberculosis (TB) y COVID-19 Lo que debes saber-OPS.** [Internet]. 2020 [citado 12 May 2020]:[aprox. 10 p.]. Disponible en: [https://drive.google.com/file/d/1cYhWvRB7O6Z7mcykWBriR3H2BPiHSGID/view?usp=drive\\_web](https://drive.google.com/file/d/1cYhWvRB7O6Z7mcykWBriR3H2BPiHSGID/view?usp=drive_web)
24. Vivas M. **Infografía SEFAC ¿Qué sabemos de la vacuna frente a COVID-19?** [Internet]. 2020 [citado 12 May 2020]:[aprox. 8 p.]. Disponible en: [https://drive.google.com/file/d/1vSnNUzBcEzNxap0Yxbo0Dq-90T6F5GUD/view?usp=drive\\_web](https://drive.google.com/file/d/1vSnNUzBcEzNxap0Yxbo0Dq-90T6F5GUD/view?usp=drive_web)

**Compilación:** Dra.C. Maria del Carmen González Rivero

# Noticias

1. **Alianza frente a la COVID-19: Sanofi y GSK buscan juntos una vacuna.** Gaceta Médica. Marta Riesgo. 14 abril 2020... [Leer más](#)
2. **Así es SOLIDARITY, el mayor ensayo clínico contra el coronavirus.** El megaensayo SOLIDARITY probará cuatro de los tratamientos más prometedores... [Leer más](#)
3. **Biocubafarma garantizará producción de los 22 medicamentos para la COVID-19.** ... Granma. 13 mar. 2020. A la par, se diseña un proyecto de vacuna, basado en la ... [Leer más:](#)
4. **Científicos cubanos trabajan en el diseño de una vacuna contra la COVID-19. 19 mar. 2020** · El Centro de Ingeniería Genética y Biotecnología (CIGB) de Cuba cuenta hoy con un diseño de vacuna que... [Leer más](#)
5. **Crear una “gigantesca” capacidad de producción, clave para avanzar en la vacuna de la COVID-19.** Gaceta Médica. Marta Riesgo. 20 marzo 2020... [Leer más](#)
6. **China asegura haber desarrollado una vacuna contra el COVID-19**
7. Gaceta Médica. Sandra Pulido -18 marzo 2020... [Leer más](#)
8. **Cuba contará en breve con vacuna inmunológica contra la COVID-19.** 15 abr. 2020. Científicos cubanos anunciaron que en breve el país contará con una vacuna inmunológica contra la COVID-19... [Leer más](#)
9. **¿Cuándo estará lista la vacuna contra la COVID-19?** [Leer más](#)
10. **Desarrolla Rusia tres fármacos y tres vacunas contra el coronavirus.** Cuba. 30 mar. 2020. Asimismo, los científicos rusos desarrollan varias vacunas... gama de coronavirus, no solo el actual", señaló Chejonin. ... COVID-19 y la fertilidad de los hombres... [Leer más](#)
11. **El Gobierno refuerza la I+D de la vacuna frente a la COVID-19 con 30 millones.** Gaceta Médica. Carlos B. Rodríguez -17 marzo 2020... [Leer más](#)
12. **El genoma de la planta que puede ser utilizado en la producción de vacunas contra la COVID-19.** Gaceta Médica. Sandra Pulido -13 abril 2020... [Leer más](#)
13. **El médico que prepara la vacuna israelí contra la COVID-19.** 3 abr. 2020 · El equipo de biotecnología MIGAL está trabajando en una vacuna para la COVID-19... [Leer más](#)
14. **En fase de desarrollo 70 vacunas contra el nuevo coronavirus, informa la OMS** ...15 abr. 2020 · Y hasta ahora, son 70 las vacunas contra el coronavirus que están en estudio a ... Cuba también busca una vacuna específica para prevenir la COVID-19.... [Leer más](#)
15. **Fármacos cubanos frente a la COVID-19 ¿cuáles van a la avanzada?...** [Leer más](#)



16. **Fármacos y terapias que están siendo testados para tratar el coronavirus publicado en la web de la Agencias de Medicinas de Dinamarca...** [Leer más](#)
17. Infomed, Portal de la Red de Salud de Cuba. **Información actualizada en Infomed sobre la COVID-19. Vacunas y Salud: Una mirada alerta desde la actualidad...** [Leer más](#)
18. **Johnson & Johnson establece un plan de desarrollo acelerado para la vacuna frente a la COVID-19.** Gaceta Médica. Carmen M. López -31 marzo 2020... [Leer más](#)
19. **La USC se une a la búsqueda de la vacuna contra la COVID-19.** Gaceta Médica. Sandra Pulido -14 abril 2020... [Leer más](#)
20. **La Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) ha publicado un listado de estrategias terapéuticas potenciales que incluye el antiviral REMDESIVIR, a combinación de los fármacos LOPINAVIR Y RITONAVIR...** [Leer más](#)
21. **La fase I con 45 participantes sanos de los ensayos de la primera vacuna.** En el Instituto de Investigación de la Salud de Kaiser Permanente de Washington (Seattle) en Estados Unidos el 16 de marzo comenzó el primer ensayo en humanos de una potencial vacuna en Estados Unidos. Con una inyección en el brazo de una voluntaria, el 16 de marzo comenzaba... [Leer más](#)
22. **Mantener la vacunación y recuperar dosis: prioridades en tiempos de la COVID-19.** Gaceta Médica Santiago. Nieves Sebastián -24 abril 2020... [Leer más](#)
23. **¿Podremos vacunar a todas las personas necesarias contra la COVID-19 en España?** Gaceta Médica. Santiago de Quiroga. 2 mayo 2020... [Leer más](#)
24. **¿Qué sabemos sobre los distintos tratamientos y vacunas que se están investigando contra el coronavirus? ...** [Leer más](#)
25. **Sanidad publica las prioridades de vacunación en tiempos de la COVID-19.** Gaceta Médica. Marta Riesgo -30 marzo 2020... [Leer más](#)
26. **18 proyectos con más de 48 millones para investigar sobre la COVID-19...** [Leer más](#)

**Compilación:** Dra.C. Maria del Carmen González Rivero

Equipo [Bibliografía](#) y DSI de la Biblioteca Médica Nacional.  
Dra.C. [Maria del Carmen González Rivero](#) / Lic. [Sonia Santana Arroyo](#)/  
Dirección: Lic. [Yanet Lujardo Escobar](#)